

# Grace Christou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7397863/publications.pdf>

Version: 2024-02-01

17  
papers

93  
citations

1477746

6  
h-index

1372195

10  
g-index

17  
all docs

17  
docs citations

17  
times ranked

224  
citing authors

#	ARTICLE	IF	CITATIONS
1	The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes. <i>Annals of Hematology</i> , 2022, 101, 1023-1030.	0.8	3
2	Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2295-2297.	0.6	7
3	The Impact of Oral Hypoglycemics and Statins on Outcomes in Myelodysplastic Syndromes. <i>Blood</i> , 2021, 138, 3064-3064.	0.6	1
4	An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring. <i>Leukemia</i> , 2020, 34, 1394-1406.	3.3	23
5	Revised 15-item MDS-specific frailty scale maintains prognostic potential. <i>Leukemia</i> , 2020, 34, 3434-3438.	3.3	8
6	Selecting the optimal targeted therapy for relapsed B-acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2271-2273.	0.6	0
7	Fatigue, However Measured, Continues to Refine Prognosis in Higher Risk MDS: An MDS-CAN Study. <i>Blood</i> , 2020, 136, 41-43.	0.6	1
8	High Transfusion Dependence and Serum Ferritin but Not Transferrin Saturation Predict Inferior Clinical Outcomes in Patients with MDS. <i>Blood</i> , 2020, 136, 47-48.	0.6	0
9	Evaluating dose-limiting toxicities of MDM2 inhibitors in patients with solid organ and hematologic malignancies: A systematic review of the literature. <i>Leukemia Research</i> , 2019, 86, 106222.	0.4	12
10	Prognostic Performance of Frailty Measures in MDS Patients Treated with Hypomethylating Agents. <i>Blood</i> , 2019, 134, 4245-4245.	0.6	3
11	Acute Myeloid Leukemia (AML) Treated with Azacitidine: Survival Outcomes for Patients Who Complete More Than Six Cycles Are Similar to High-Risk Myelodysplastic Syndrome/Low Blast Count AML. <i>Blood</i> , 2019, 134, 5156-5156.	0.6	0
12	Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less. <i>Blood</i> , 2019, 134, 3263-3263.	0.6	0
13	Intermittent Transfusion Independence Is Associated with Improved Overall Survival in Patients with Transfusion Dependent MDS. <i>Blood</i> , 2019, 134, 5416-5416.	0.6	1
14	Optimal transfusion practices after allogeneic hematopoietic cell transplantation: a systematic scoping review of evidence from randomized controlled trials. <i>Transfusion</i> , 2016, 56, 2607-2614.	0.8	10
15	Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantation. <i>Transfusion</i> , 2015, 55, 253-258.	0.8	14
16	A pilot prospective study of the vascular repair response following red cell transfusion in critically ill patients. <i>Transfusion Medicine</i> , 2013, 23, 94-99.	0.5	1
17	Factors associated with the avoidance of red blood cell transfusion after hematopoietic stem cell transplantation. <i>Transfusion</i> , 2012, 52, 2049-2054.	0.8	9